Fig. 1.

Phosphorylated tau is increased in cholinesterase inhibitor-treated AD cases compared to non-treated AD cases. Frontal and temporal cortical sections were immunolabelled with antibodies to Aβ and Ser 202-phospho tau and visualised with avidin-biotin-peroxidase and DAB. Computer-assisted image analysis software was used to assess the percentage area of section occupied by Aβ and phosphorylated tau. Scatterplots show the distribution of Aβ (a) and phosphorylated tau (b). The horizontal bars indicate the median values and the interquartile ranges